AU2018312448B2 - 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs - Google Patents

1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs Download PDF

Info

Publication number
AU2018312448B2
AU2018312448B2 AU2018312448A AU2018312448A AU2018312448B2 AU 2018312448 B2 AU2018312448 B2 AU 2018312448B2 AU 2018312448 A AU2018312448 A AU 2018312448A AU 2018312448 A AU2018312448 A AU 2018312448A AU 2018312448 B2 AU2018312448 B2 AU 2018312448B2
Authority
AU
Australia
Prior art keywords
cancer
alkyl
optionally substituted
unsubstituted
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2018312448A
Other languages
English (en)
Other versions
AU2018312448A1 (en
Inventor
Brant Clayton BOREN
Kevin Duane Bunker
Peter Qinhua HUANG
Hui Liu
Sunil Paliwal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Recurium IP Holdings LLC
Original Assignee
Recurium IP Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium IP Holdings LLC filed Critical Recurium IP Holdings LLC
Publication of AU2018312448A1 publication Critical patent/AU2018312448A1/en
Application granted granted Critical
Publication of AU2018312448B2 publication Critical patent/AU2018312448B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2018312448A 2017-08-01 2018-07-31 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs Ceased AU2018312448B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762539734P 2017-08-01 2017-08-01
US62/539,734 2017-08-01
PCT/US2018/044580 WO2019028008A1 (en) 2017-08-01 2018-07-31 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES

Publications (2)

Publication Number Publication Date
AU2018312448A1 AU2018312448A1 (en) 2020-02-13
AU2018312448B2 true AU2018312448B2 (en) 2022-09-15

Family

ID=65233095

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018312448A Ceased AU2018312448B2 (en) 2017-08-01 2018-07-31 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs

Country Status (16)

Country Link
US (2) US11124518B2 (enExample)
EP (1) EP3661918B1 (enExample)
JP (1) JP7203816B2 (enExample)
KR (1) KR20200034781A (enExample)
CN (1) CN111094253B (enExample)
AR (1) AR112774A1 (enExample)
AU (1) AU2018312448B2 (enExample)
BR (1) BR112020002104A2 (enExample)
CA (1) CA3071405A1 (enExample)
ES (1) ES2980537T3 (enExample)
IL (1) IL272262A (enExample)
MX (1) MX2020001235A (enExample)
RU (1) RU2020105058A (enExample)
SG (1) SG11202000789WA (enExample)
TW (1) TW201910335A (enExample)
WO (1) WO2019028008A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3078945A1 (en) 2017-10-09 2019-04-18 Nuvation Bo Inc. Heterocyclic compounds and uses thereof
EP3694861A4 (en) * 2017-10-09 2021-05-19 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS AND USES THEREOF
CA3088997A1 (en) * 2018-02-28 2019-09-06 The Regents Of The University Of Colorado, A Body Corporate Wee1 kinase inhibitors and methods of treating cancer using the same
BR112020018286A2 (pt) * 2018-03-09 2020-12-29 Recurium Ip Holdings, Llc 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas
CN110872296B (zh) * 2018-08-31 2023-05-23 上海弘翊生物科技有限公司 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用
JP2022526831A (ja) * 2019-04-09 2022-05-26 ニューベイション・バイオ・インコーポレイテッド ヘテロ環式化合物およびその使用
US20220169646A1 (en) * 2019-04-09 2022-06-02 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210380A1 (en) * 2019-04-09 2020-10-15 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
WO2020210320A1 (en) * 2019-04-11 2020-10-15 Recurium Ip Holdings, Llc Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
BR112021026618A2 (pt) 2019-06-28 2022-06-07 Shanghai Pharmaceuticals Holding Co Ltd Composto de pirazolpirimidina, método de preparação do mesmo e aplicações do mesmo
CN112142748B (zh) * 2019-06-28 2023-07-04 上海医药集团股份有限公司 一种吡唑酮并嘧啶类化合物、其制备方法及应用
CN112442049A (zh) * 2019-09-03 2021-03-05 微境生物医药科技(上海)有限公司 作为Wee1抑制剂的嘧啶衍生物
WO2021097139A1 (en) 2019-11-15 2021-05-20 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
CA3165472A1 (en) * 2019-12-20 2021-06-24 Recurium Ip Holdings, Llc Combinations
CA3182270A1 (en) * 2020-05-15 2021-11-18 Recurium Ip Holdings, Llc Mono- and combination therapies
AU2021290701A1 (en) 2020-06-17 2023-02-02 Wigen Biomedicine Technology (shanghai) Co., Ltd. Pyrazolo(3,4-d)pyrimidine-3-ketone derivative as Wee-1 inhibitor
KR20230038523A (ko) 2020-07-09 2023-03-20 리커리엄 아이피 홀딩스, 엘엘씨 Wee1 억제제의 염 및 형태
CN114805357B (zh) * 2021-01-21 2023-12-19 四川大学 一种靶向setdb1-ttd的小分子抑制剂及其制药用途
EP4332104A4 (en) * 2021-04-30 2025-04-16 Wigen Biomedicine Technology (Shanghai) Co., Ltd. Fused ring compound as a WEE-1 inhibitor, as well as production process and use thereof
US20240254123A1 (en) * 2021-06-04 2024-08-01 Aprea Therapeutics, Inc. Pyridopyrimidine derivatives useful as wee1 kinase inhibitors
CN117751122B (zh) * 2021-08-11 2026-07-24 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
WO2023045942A1 (zh) * 2021-09-22 2023-03-30 微境生物医药科技(上海)有限公司 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物
WO2023166080A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor
WO2026112362A1 (en) * 2024-11-21 2026-05-28 Recurium Ip Holdings, Llc Wee1 inhibitors and methods for treating cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074985A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2007126122A1 (en) * 2006-04-27 2007-11-08 Banyu Pharmaceutical Co., Ltd. Dihydropyrazolopyrimidinone derivatives
EP2213673A1 (en) * 2007-10-23 2010-08-04 Banyu Pharmaceutical Co., Ltd. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
WO2018011569A1 (en) * 2016-07-12 2018-01-18 Almac Discovery Limited Wee-1 inhibiting pyrazolopyrimidinone compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT201900344T1 (it) * 2012-09-10 2019-07-11 Principia Biopharma Inc Composti di pirazolopirimidina come inibitori di chinasi

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006074985A1 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
WO2007126122A1 (en) * 2006-04-27 2007-11-08 Banyu Pharmaceutical Co., Ltd. Dihydropyrazolopyrimidinone derivatives
EP2213673A1 (en) * 2007-10-23 2010-08-04 Banyu Pharmaceutical Co., Ltd. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
US8329711B2 (en) * 2007-10-23 2012-12-11 Msd K.K. Pyridone-substituted-dihydropyrazolopyrimidinone derivative
WO2018011569A1 (en) * 2016-07-12 2018-01-18 Almac Discovery Limited Wee-1 inhibiting pyrazolopyrimidinone compounds

Also Published As

Publication number Publication date
IL272262A (en) 2020-03-31
EP3661918C0 (en) 2024-05-08
EP3661918A1 (en) 2020-06-10
US20200157112A1 (en) 2020-05-21
EP3661918B1 (en) 2024-05-08
JP2020529993A (ja) 2020-10-15
CA3071405A1 (en) 2019-02-07
MX2020001235A (es) 2020-07-20
RU2020105058A3 (enExample) 2021-11-17
US11124518B2 (en) 2021-09-21
TW201910335A (zh) 2019-03-16
RU2020105058A (ru) 2021-09-02
EP3661918A4 (en) 2021-05-12
US20210317124A1 (en) 2021-10-14
BR112020002104A2 (pt) 2020-08-04
AU2018312448A1 (en) 2020-02-13
SG11202000789WA (en) 2020-02-27
JP7203816B2 (ja) 2023-01-13
AR112774A1 (es) 2019-12-11
KR20200034781A (ko) 2020-03-31
WO2019028008A1 (en) 2019-02-07
CN111094253B (zh) 2023-08-29
ES2980537T3 (es) 2024-10-01
CN111094253A (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
EP3661918B1 (en) 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-one analogs
JP7614255B2 (ja) 置換１，２－ジヒドロ－３Ｈ－ピラゾロ［３，４－ｄ］ピリミジン－３－オン
WO2023287730A1 (en) Tricyclic compounds
ES2834093T3 (es) Inhibidores de proteína quinasa heterocíclicos
WO2020210320A1 (en) Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
RU2847224C2 (ru) Замещенные 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-оны
RU2812726C2 (ru) Замещенные 1,2-дигидро-3н-пиразоло[3,4-d]пиримидин-3-оны
HK40043303B (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
HK40043303A (en) Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired